Literature DB >> 18945751

The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.

Erin M Dunbar1, Mathew P Buzzeo, Jeff B Levine, Jesse D Schold, Herwig-Ulf Meier-Kriesche, Vijay Reddy.   

Abstract

BACKGROUND: Natural killer cells are known to have anti-tumor activity in haploidentical hematopoietic stem cell transplantation. We hypothesized that reconstituted circulating natural killer cells may be associated with improved relapse-free survival after HLA-matched hematopoietic stem cell transplantation. DESIGN AND METHODS: Serial peripheral blood absolute natural killer cell counts were prospectively measured by flow cytometry of lymphocytes expressing CD56 and CD16 in 167 patients. Cluster analysis was used at engraftment and 60 days post-transplant to distinguish patients with high and low absolute natural killer cell counts. At engraftment 80 patients had high counts (> 22.2/mm3) and 43 had low counts. At 60 days post-transplant 84 patients had high counts (> 18.2/mm3) and 38 had low counts. The primary study end-points were death, relapse and acute graft-versus-host disease. The median follow-up was 373 days (range, 67-1767).
RESULTS: Among patients given reduced intensity conditioning, a low absolute natural killer cell count at 60 days post-transplant was independently associated with relapse [adjusted hazard ratio (AHR) = 28.4, 95% confidence interval (CI) 4.3-186.4] and death (AHR = 17.5, 95% CI 4.3-71.3). Furthermore, patients given reduced intensity conditioning who had a high absolute natural killer cell count at 60 days had a significantly better 1-year survival than those with a low count by Kaplan-Meier analysis (83% vs. 11%, p<0.001). Multivariate analysis confirmed that low 60-day absolute natural killer count in patients given reduced intensity conditioning was independently associated with an increase in relapse or death (AHR = 20.22, 95% CI 4.76-85.40). In contrast, there was no significant association between 60-day absolute natural killer cell counts and clinical outcomes in patients receiving myeloablative conditioning. There was no significant association between absolute natural killer cell count and graft-versus-host disease.
CONCLUSIONS: High natural killer cell reconstitution is associated with reduced relapse and death without an increased incidence of graft-versus-host-disease after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Measuring reconstituted natural killer cells expressing CD56(+)/CD16(+) post-transplant may have novel prognostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945751     DOI: 10.3324/haematol.13033

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  20 in total

Review 1.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 2.  NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

Authors:  Catharina H M J Van Elssen; Stefan O Ciurea
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

3.  The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT.

Authors:  Luke Maggs; Francesca Kinsella; Y L Tracey Chan; Suzy Eldershaw; Duncan Murray; Jane Nunnick; Joanne Bird; Charles Craddock; Jianmin Zuo; Ram Malladi; Paul Moss
Journal:  Blood Adv       Date:  2017-08-21

4.  Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.

Authors:  Ioannis Politikos; Jessica A Lavery; Patrick Hilden; Christina Cho; Taylor Borrill; Molly A Maloy; Sergio A Giralt; Marcel R M van den Brink; Miguel-Angel Perales; Juliet N Barker
Journal:  Blood Adv       Date:  2020-01-14

Review 5.  The immunological function of CD52 and its targeting in organ transplantation.

Authors:  Yang Zhao; Huiting Su; Xiaofei Shen; Junfeng Du; Xiaodong Zhang; Yong Zhao
Journal:  Inflamm Res       Date:  2017-03-10       Impact factor: 4.575

6.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

Authors:  Stefan O Ciurea; Jolie R Schafer; Roland Bassett; Cecele J Denman; Kai Cao; Dana Willis; Gabriela Rondon; Julianne Chen; Doris Soebbing; Indreshpal Kaur; Alison Gulbis; Sairah Ahmed; Katayoun Rezvani; Elizabeth J Shpall; Dean A Lee; Richard E Champlin
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

7.  Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

Authors:  David A Rizzieri; Robert Storms; Dong-Feng Chen; Gwynn Long; Yiping Yang; Daniel A Nikcevich; Cristina Gasparetto; Mitchell Horwitz; John Chute; Keith Sullivan; Therese Hennig; Debashish Misra; Christine Apple; Megan Baker; Ashley Morris; Patrick G Green; Vic Hasselblad; Nelson J Chao
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-24       Impact factor: 5.742

8.  Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Authors:  David A Rizzieri; Christopher Crout; Robert Storms; Jared Golob; Gwynn D Long; Cristina Gasparetto; Keith M Sullivan; Mitchell Horwitz; John Chute; Anand S Lagoo; Ashley Morris; Anne Beaven; Yiping Yang; Bercedis Peterson; Zhiguo Li; Nelson J Chao
Journal:  Cancer Invest       Date:  2011-01       Impact factor: 2.176

Review 9.  Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses.

Authors:  Saar Gill; Janelle A Olson; Robert S Negrin
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-02       Impact factor: 5.742

10.  Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

Authors:  Monzr M Al Malki; Mary Horowitz; Rupert Handgretinger; Wing Leung; Denis-Claude Roy; Xiao-Jun Huang; Ephraim Fuchs; Franco Locatelli; Didier Blaise; Shin Mineishi; Massimo Martelli; Jeffrey Miller; Carl June; Hui-Sheng Ai; Leo Luznik; Domenico Mavilio; Enrico Lugli; Marcel R M van den Brink; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-13       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.